Related Experiment Videos
Scleroderma and related disorders: therapeutic aspects
1Centre for Rheumatology, Royal Free and University College Medical School, London, UK.
Summary
Systemic sclerosis management has improved with better diagnosis and organ-specific treatments. However, truly disease-modifying therapies remain elusive, though complications like pulmonary fibrosis and hypertension are better managed.
Area of Science:
- Rheumatology
- Immunology
- Internal Medicine
Background:
- Systemic sclerosis is a complex multisystem connective tissue disease with significant morbidity.
- Understanding of its pathogenesis has advanced, leading to improved diagnostic and assessment tools.
- Organ-specific complications significantly impact patient outcomes.
Purpose of the Study:
- To review current management strategies for systemic sclerosis.
- To discuss evidence for and against disease-modifying agents.
- To explore novel therapeutic approaches for this condition.
Main Methods:
- Review of current literature on systemic sclerosis management.
- Analysis of clinical trial data for disease-modifying agents.
- Discussion of therapeutic advances for visceral complications.
Main Results:
- Significant progress in managing systemic sclerosis complications including renal crisis, pulmonary fibrosis, and pulmonary hypertension.
- Limited evidence supporting the efficacy of many current disease-modifying therapies.
- Advances in treating scleroderma-associated Raynaud's phenomenon.
Conclusions:
- While organ-specific treatments have improved, effective disease-modifying therapies for systemic sclerosis are still needed.
- Critical evaluation of existing treatments is necessary.
- New therapeutic strategies are under investigation for this challenging disease.